Results 11 to 20 of about 12,566,431 (163)

Identification of the Profile of the Patients with Hemophilia B Eligible for Treatment with Nonacog Alfa Once-Weekly

Reports, 2020
This study aimed to identify the characteristics of patients with hemophilia B eligible for once-weekly treatment with Nonacog alfa. Methods: A survey was conducted in 14 Hemophilia (HCs) of Italy.
Dorina Cultrera, Raimondo De Cristofaro, Paola Giordano, Silvia Linari, Silvia Macchi, Renato Marino, Angelo Claudio Molinari, Angiola Rocino, Cristina Santoro, Piercarla Schinco, Sergio Siragusa, Giuseppe Tagariello, Annarita Tagliaferri, Ezio Zanon, Massimo Morfini   +14 more
doaj   +1 more source

A Case of Heel Reconstruction with a Reverse Sural Artery Flap in a Hemophilia B Patient

Archives of Plastic Surgery, 2012
Hemophilia B is a rare blood coagulation disorder. Complications such as bleeding and hematoma can cause necrosis of flaps, wound disruption, and the disturbance of wound healing.
Byung Kwon Lee, Jeong Su Shim
doaj   +1 more source

Identification and Genetic Analysis of a Factor IX Gene Intron 3 Mutation in a Hemophilia B Pedigree in China

Turkish Journal of Hematology, 2014
OBJECTIVE: Hemophilia B is caused by coagulation defects in the factor IX gene located in Xq27.1 on the X chromosome. A wide range of mutations, showing extensive molecular heterogeneity, have been described in hemophilia B patients.
Dong Hua Cao, Xiao Li Liu, Kai Mu, Xiang Wei Ma, Jing Li Sun, Xiao Zhong Bai, Chang Kun Lin, Chun Lian Jin   +7 more
doaj   +1 more source

Factor IX p.A37V mutation causes severe bleeding in a patient with phenprocoumon therapy

European Journal of Medical Research, 2021
Background Bleeding is the most common complication of oral anticoagulants, due to inadequate dosing. Case presentation This report describes the clinical course of a patient who developed severe bleeding under therapy with phenprocoumon, despite an INR ...
Nils Mülling, Vivian Rosery, H. Christian Reinhardt, Maher Hanoun   +3 more
doaj   +1 more source

Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

New England Journal of Medicine, 2014
BACKGROUND In patients with severe hemophilia B, gene therapy that is mediated by a novel self-complementary adeno-associated virus serotype 8 (AAV8) vector has been shown to raise factor IX levels for periods of up to 16 months.
A. Nathwani, U. Reiss, E. Tuddenham, Cecilia Rosales, P. Chowdary, J. McIntosh, M. della Peruta, Elsa Lhériteau, Nishali Patel, D. Raj, A. Riddell, J. Pie, S. Rangarajan, D. Bevan, M. Recht, Yu-min P Shen, K. Halka, E. Basner-Tschakarjan, F. Mingozzi, K. High, J. Allay, M. Kay, C. Ng, Junfang Zhou, M. Cancio, C. Morton, J. Gray, D. Srivastava, A. Nienhuis, A. Davidoff   +29 more
semanticscholar   +1 more source

Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.

Blood, 2018
Gene therapy for hemophilia B aims to ameliorate bleeding risk and provide endogenous factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for FIX concentrate.
Wolfgang A. Miesbach, K. Meijer, M. Coppens, P. Kampmann, R. Klamroth, R. Schutgens, M. Tangelder, G. Castaman, J. Schwäble, H. Bonig, E. Seifried, F. Cattaneo, C. Meyer, F. Leebeek   +13 more
semanticscholar   +1 more source

Seroprevalence of Hepatitis B and Hepatitis C in People with Haemophilia at a Tertiary Care Centre, Assam, India: A Cross-sectional Study [PDF]

Journal of Clinical and Diagnostic Research
Introduction: Prior to the advent of recombinant factor products, the treatment of haemophilia was mainly based on the administration of direct blood products like whole blood, Fresh Frozen Plasma (FFP), and cryoprecipitates. This led to a high incidence
Anupam Dutta, Luish Borboruah, Papori Gogoi   +2 more
doaj   +1 more source

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.

Blood, 2016
A global phase 3 study evaluated the pharmacokinetics, efficacy, and safety of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in 63 previously treated male patients (12-61 years) with severe hemophilia B (factor IX [FIX ...
E. Santagostino, U. Martinowitz, T. Lissitchkov, Brigitte Pan-Petesch, H. Hanabusa, J. Oldenburg, L. Boggio, C. Négrier, I. Pabinger, Mario von Depka Prondzinski, C. Altisent, G. Castaman, Koji Yamamoto, M. Álvarez‐Román, Christine Voigt, N. Blackman, Iris Jacobs   +16 more
semanticscholar   +1 more source

The B-team: Equal but different?

The Journal of Haemophilia Practice, 2021
As a person with haemophilia B, I have known there are differences between haemophilia A and haemophilia B and their respective treatment throughout my life – though I was shocked when I learnt about the impact inhibitors can have when it comes to ...
Pembroke Luke
doaj   +1 more source

CRISPR/Cas9‐mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse

EMBO Molecular Medicine, 2016
The X‐linked genetic bleeding disorder caused by deficiency of coagulator factor IX, hemophilia B, is a disease ideally suited for gene therapy with genome editing technology. Here, we identify a family with hemophilia B carrying a novel mutation, Y371D,
Yuting Guan, Yanlin Ma, Qi Li, Zhenliang Sun, Lie Ma, Lijuan Wu, Liren Wang, L. Zeng, Yanjiao Shao, Yuting Chen, Ning Ma, Wenqing Lu, Kewen Hu, Honghui Han, Yanhong Yu, Yuanhua Huang, Mingyao Liu, Dali Li   +17 more
semanticscholar   +1 more source